Imunon (NASDAQ:IMNN – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.
Imunon (NASDAQ:IMNN – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.04. On average, analysts expect Imunon to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Imunon Stock Up 1.1 %
Imunon stock traded up $0.01 during midday trading on Tuesday, hitting $0.99. 198,227 shares of the company were exchanged, compared to its average volume of 993,945. Imunon has a fifty-two week low of $0.48 and a fifty-two week high of $3.65. The business has a fifty day simple moving average of $1.03 and a two-hundred day simple moving average of $1.21.
Analysts Set New Price Targets
Read Our Latest Research Report on Imunon
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Featured Articles
- Five stocks we like better than Imunon
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Palantir Cracks $50, Is There Still Time to Get on Board?
- How to Calculate Inflation Rate
- Insider Buying Signals Upside for These 3 Stocks
- Earnings Per Share Calculator: How to Calculate EPS
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.